VAKCINA

Dodaje da je tu reč i o ogromnom novcu i da su se pojavila 104 proizvođača vakcina u svetu, što svedoči da je farmaceutska industrija osetila da je u ovome mnogo novca.

Ferenc Puskás wrote:
Hm, kad bi neki od rezidentnih istoričara rekli u par riječi o posljedicama epidemija u prošlosti. Što laički znam, epidemije su mnoge prilično upropastile.

ćaća wrote:Ali srpska agencija za lekove radi na iSpiTIvAnJu vAkcInE...

Poslaće nam i NekE rEaGEnSe!

Marius Lăcătuș wrote:Znači sad Burundi navija za koronu?

Marius Lăcătuș wrote:

kapetanm wrote:Nije tako crno. Javlja mi se da:
- ce se ispostaviti da vakcine ne deluju
- postoji nov soj koji se brzometno siri a za koji nema vakcine

To je moje vidjenje 2021

možemo nagađati ali je razumno očekivati da stvari neće ići baš 100% ovako kako ih sada predstavljaju - i politici i nauci ide na ruku da se predstave kao pobednici. kamo sreće da zaista bude tako.

mislim da je jedino izvesno da ćemo izaći sa izmenjenom kulturom života - za neke od nas maske će ostati trajno sredstvo prevencije, neće više biti razgovora izbliza, povišenog tona glasa, prisnosti u casual ophođenju. distanca će ostati trajno u našim životima. ovo ostalo - vakcine, preventiva i slično - može da bude ali ne mora da znači. u nečemu moram da se složim sa nepopularnom sisatom ministarkom - svaki čovek ove planete će biti svoj KŠ i kako poseje tako će i požnjeti.

Mr.Pink wrote:od toga nemos se zivi

pricam o stimulusima od par soma dolara na mesecnom nivou

#BREAKING EU regulator approves Pfizer-BioNTech vaccine for EU: EMA chief pic.twitter.com/Yf7yCFFvIu

— AFP News Agency (@AFP) December 21, 2020

The Oxford vaccine is expected to be approved within days of Christmas, kickstarting a massive drive to give jabs to millions of people in January, The Telegraph can reveal.

Senior Whitehall sources believe the Medicines and Healthcare Regulatory Agency (MHRA) will authorise the vaccines on December 28 or 29 after final data is provided to the regulator on Monday.

Football stadia and other sites across the country will then be opened from the first week of January, to allow mass vaccinations on a scale never seen before in the UK.

BREAKING: Russia’s President Vladimir Putin @KremlinRussia_E is having a video call with AstraZeneca @AstraZeneca company, Russian Direct Investment Fund @rdif_press, the Gamaleya Center, and R-Pharm company.

— Sputnik V (@sputnikvaccine) December 21, 2020

A nurse at a hospital in Connecticut became one of the first people in the United States to receive the Moderna Covid-19 vaccine on Monday.

Mandy Delgado, who works for Hartford Healthcare, was administered the shot around 11:40 am (1640 GMT), according to a live feed of the event.

"I'm excited. I feel privileged," the critical care nurse said afterwards, to a loud round of applause.

The first Moderna inoculations come after the US Food and Drug Administration (FDA) announced late Friday that it had granted emergency approval for the vaccine.

It also comes exactly a week after the US, the country hardest hit by the coronavirus, began administering the Pfizer-BioNTech vaccine.

The Moderna vaccine can be stored at -20 degrees Celsius (-4 degrees Fahrenheit), much lower than Pfizer's vaccine which must be stored at -70 degrees Celsius (-94 degrees Fahrenheit), making it easier to distribute.

Since the FDA granted Pfizer-BioNTech vaccine emergency authorization one week ago, some 2.9 million doses have been delivered in the US, officials say.

Life will not ‘go back to normal’ until at least half the population is vaccinated


Coronavirus modelling indicates that even if high-risk groups are vaccinated, death rates and hospitalisations would continue if measures were relaxed before the virus had been controlled in the general population.

21st December, 2020 at 17:23

Vaccination alone will not be enough to bring coronavirus in the community down to “very low levels”, and social restrictions may have to continue until around 50 per cent of the population has been vaccinated, an expert has said.
Many people have been hoping for a return to normal once the elderly and those most at risk from COVID-19 have received the jab.
But scientists say this might not be enough to see an end to measures such as social distancing and wearing face masks.
They suggest restrictions may be needed until at least half of the UK’s population has had the coronavirus vaccine.
Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, said vaccination alone will not be enough to bring the virus circulating in the community to “very low levels”.
“We actually need to have the absolute amount of virus circulating to be very low,” said Evans at a press briefing arranged by the Science Media Centre.
“And we won’t do that by vaccination alone until we’re getting 50 per cent of the population vaccinated or more, and that’s going to be quite a bit of a long way off yet.
“So I fear that the sort of restrictions we have, the non-medical interventions, are going to need to be carried on.”
“I think if people take these seriously, then it’s possible for various economic activities to go ahead, but you have to make sure that you are keeping to the non-medical interventions, being aware and behaving as if every person you contact has got the virus. And that you have it as well,” added Evans.
“And when you behave in a way that realises that, and that the consequences for either you or the person around you getting the virus can be very serious, then it changes people’s behaviour.
“And we’re going to have to go on doing that for quite a long time.”
Health Secretary Matt Hancock said that as of 8am on Saturday 19 December 2020, 350,000 people had been vaccinated.
Adam Finn, professor of paediatrics at the University of Bristol, said that even if the elderly are vaccinated, social restrictions may have to continue for some time.
“I think the modelling is very clear that even if you had high coverage and high levels of protection in the high-risk groups, you would still see epidemics, and large numbers of hospitalisations and deaths if you relax the measures before you have a broader control of viral circulation in the population at large,” said Finn.
“So I think the idea that you can immunise a large proportion of the elderly and then kind of go back to normal is misguided.
“I think that none of the models suggest that that’s going to be possible.”
Peter Openshaw, professor of experimental medicine at Imperial College London, said he is concerned about the hard to reach in the community – people who are very doubtful about vaccines or those not very well informed. He said this is something that needs to be focused on.
He added that the efficacy of the Oxford-AstraZeneca vaccine, which is yet to receive regulatory approval, against transmission may be “considerable” even if it is not as effective as the other options.
There have been some concerns the Oxford vaccine may not be as good as preventing symptomatic disease as the others, but the experts suggested it would be adequate for very strong population-wide effects if widely deployed.
The experts said it is not yet possible to say how much of the population needs to be vaccinated to achieve herd immunity.
They explained that while there is insufficient evidence on how effective the vaccines are at reducing transmission, the Pfizer vaccine developed with BioNTech and the Moderna jabs have demonstrated such high efficacy, it would be surprising if there was no impact on transmission.
Openshaw explained that as well as the elderly, there has to be concern about the effects of long COVID in relatively young people.
He said he found the idea of his colleagues or his relatives becoming affected by long COVID “terrifying”.
“We shouldn’t stop vaccinating once we have just vaccinated the high risk,” said Openshaw. “I think we have to get the population vaccinated and I think the prospects of vaccines preventing long COVID are quite good.”

How do scientists develop vaccines for new viruses?

Vaccines work by fooling our bodies into thinking that we’ve been infected by a virus. Our body mounts an immune response, and builds a memory of that virus which will enable us to fight it in the future.
Viruses and the immune system interact in complex ways, so there are many different approaches to developing an effective vaccine. The two most common types are inactivated vaccines (which use harmless viruses that have been ‘killed’, but which still activate the immune system), and attenuated vaccines (which use live viruses that have been modified so that they trigger an immune response without causing us harm).
A more recent development is recombinant vaccines, which involve genetically engineering a less harmful virus so that it includes a small part of the target virus. Our body launches an immune response to the carrier virus, but also to the target virus.
Over the past few years, this approach has been used to develop a vaccine (called rVSV-ZEBOV) against the Ebola virus. It consists of a vesicular stomatitis animal virus (which causes flu-like symptoms in humans), engineered to have an outer protein of the Zaire strain of Ebola.
Vaccines go through a huge amount of testing to check that they are safe and effective, whether there are any side effects, and what dosage levels are suitable. It usually takes years before a vaccine is commercially available.
Sometimes this is too long, and the new Ebola vaccine is being administered under ‘compassionate use’ terms: it has yet to complete all its formal testing and paperwork, but has been shown to be safe and effective. Something similar may be possible if one of the many groups around the world working on a vaccine for the new strain of coronavirus (SARS-CoV-2) is successful.

La vaccination débutera dans les 27 pays de l'UE les 27, 28 et 29 décembre.
À tous les sceptiques, à tous ceux qui en doutaient, l'Europe a montré qu'elle était bien plus qu'un grand marché : une communauté de destin.
C'est sa singularité, et c'est notre force face à la crise. https://t.co/iKiEYeWnSM

— Jean Castex (@JeanCASTEX) December 21, 2020